Comparative analysis of molecular alterations in fibroadenomas associated or not with breast cancer

Archives of Surgery

Volumn 138, Issue 3, 2003, Pages 291-295

  Franco, Noreli ^a   Arnould, Laurent ^a   Mege, Florence ^a   Picard, Samy Felix ^a   Arveux, Patrick ^a   Lizard Nacol, Sarab ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST DISEASE; BREAST FIBROADENOMA; CARCINOGENESIS; CARCINOMA IN SITU; CHROMOSOME; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; NEOPLASM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FIBROADENOMA; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES;

EID: 0037334696     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.138.3.291     Document Type: Article

References (37)

1. Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331:10-15.
2. Page DL, Jensen RA, Simpson JF. Premalignant and malignant disease of the breast: the roles of the pathologist. Mod Pathol. 1998;11:120-128.
3. McPherson K, Steel CM, Dixon JM. ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000;321:624-628.
4. Ciatto S, Bonardi R, Zappa M, Giorgi D. Risk of breast cancer subsequent to histological or cliinical diagnosis of fibroadenoma - retrospective longitudinal study of 3938 cases. Ann Oncol. 1997;8:297-300.
5. Larson PS, de las Morenas A, Cupples LA, Huang K, Rosenberg CL. Genetically abnormal clones in histologically normal breast tissue. Am J Pathol. 1998;152:1591-1598.
6. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 1996;274:2057-2059.
7. Phelan CM, Borg A, Cuny M, et al. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res. 1998;58:1004-1012.
8. Laake K, Odegard A, Andersen TI, et al. Loss of heterozygosity at 11 q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes Chromosomes Cancer. 1997;18:175-180.
9. Patel U, Grundfest-Broniatowski S, Gupta M, Banerjee S. Microsatellite instabilities at five chromosomes in primary breast tumors. Oncogene. 1994;9:3695-3700.
10. Matsumoto S, Kasumi F, Sakamoto G, Onda M, Nakamura Y, Emi M. Detailed deletion mapping of chromosome 3p in breast cancers: a 2-cM region on 3p14.3/21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors. Genes Chromosomes Cancer. 1997;20:268-274.
11. Mitelman F. Catalog of Chromosome Aberration in Cancer. 5th ed. New York, NY: Alan R Liss Inc, 1994.
12. Schmitt FC, Soares R, Gobbi H, et al. Microsatellite instability in medullary breast carcinomas. Int J Cancer. 1999;82:644-647.
13. Rosenberg CL, de las Morenas A, Huang K, Cupples LA, Faller DV, Larson PS. Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J Clin Invest. 1996;98:1095-1100.
14. Kasami M, Vnencak-Jones CL, Manning S, Dupont WD, Page DL. Loss of heterozygosity and microsateltite instability in breast hyperplasia: no obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol. 1997;150:1925-1932.
15. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998;90;697-703.
16. Euhus DM, Maitra A, Wistuba II, Alberts A, Albores-Saavedra J, Gazdar AF. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer. J Surg Res. 1999;83:13-18.
17. McCulloch RK, Sellner LN, Papadimitrou M, Turbett GR. The incidence of microsatellite instability and loss of heterozygosity in fibroadenoma of the breast. Breast Cancer Res Treat. 1998;49:165-169.
18. Millikan R, Hulka BS, Thor AD, et al. p53 mutations in benign breast tissue. J Clin Oncol. 1995;13:2293-2300.
19. Greer CE, Wheeler CM, Manos MM. PCR primer. In: Dieffenbach CW, Dvksler GS, eds. A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1995:99-104.
20. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning., In: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989:6.53-6.57.
21. Franco N, Picard SF, Mege F, Arnould L, Lizard-Nacol S. Absence of genetic abnormalities in fibroadenomas of the breast determined at p53 gene mutations and microsatellite alterations. Cancer Res. 2001;61:7955-7958.
22. Lizard-Nacol S, Lidereau R, Collin F, et al. Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res. 1995;55:4416-4419.
23. Tibiletti MG, Sessa F, Bernasconi B, et al. A large 6q deletion is a common cytogenetic alteration in fibroadenomas; pre-malignant lesions, and carcinomas of the breast. Clin Cancer Res. 2000;6:1422-1431.
24. Petersson C, Pandis N, Rizou H, et al. Karyotypic abnormalities in fibroadenomas of the breast. Int J Cancer. 1997;70:282-286.
25. Rohen C, Staats B, Bonk U, Bartnitzke S, Bullerdiek J. Significance of clonal chromosome aberrations in breast fibroadenomas. Cancer Genet Cytogenet. 1996;87:152-155.
26. Dietrich CU, Pandis N, Teixeira MR, et al. Chromosome abnormalities in benign hyperproliferative disorders of epithelial and stromal breast tissue. Int J Cancer. 1995;60:49-53.
27. Fletcher JA, Pinkus GS, Weidner N, Morton CC. Lineage- restricted clonality in biphasic solid tumors. Am J Pathol. 1991;138:1199-1207.
28. Leuschner E,. Meyer-Bolte K, Caselitz J, Bartnitzke S, Bullerdiek J. Fibroadenoma of the breast showing a translocation (6;14), a ring chromosome and two markers involving parts of chromosome 11. Cancer Genet Cytogenet. 1994;76:145-147.
29. Pandis N, Bardi G, Heim S. Interrelationship between methodological choices and conceptual models in solid tumor cytogenetics. Cancer Genet Cytogenet. 1994;76:77-84.
30. De Marchis L, Contegiacomo A, D'Amico C, et al. Microsatellite instability is correlated with lymph node-positive breast cancer. Clin Cancer Res. 1997;3:241-248.
31. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997;57:4749-4756.
32. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248-5257.
33. Nogueira AM, Carneiro F, Seruca R, et al. Microsatellite instability in hyperplastic and adenomatous polyps of the stomach. Cancer. 1999;86:1649-1656.
34. Carter BA, Page DL, Schuyler P, et al. No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. Cancer. 2001;92:30-36.
35. Tavasoli FA. Pathology of the Breast. 2nd ed. East Norwalk, Conn: Appleton & Lange; 1999:571-597.
36. Stratton MR, Collins N, Lakhani SR, Sloane JP. Loss of heterozygosity in ductal carcinoma in situ of the breast. J Pathol. 1995;175:195-201;
37. Dillon EK, de Boer WB, Papadimitriou JM, Turbett GR. Microsatellite instability and loss of heterozygosity in mammary carcinoma and its probable precursors. Br J Cancer. 1997;76:156-162.